Skip to content

Study · Measured the body's own peptide · 1993

4 results

Serum cross-reactive thymosin alpha 1 levels in rats during induction of mammary carcinoma with 7,12-dimethylbenz[a]anthracene: short- and long-term effects.

Kurl RN, Naylor PH, Barsoum AL

Cancer letters1 May 1993

PMID8513445 (opens in a new tab)DOI10.1016/0304-3835(93)90173-7 (opens in a new tab)PepBankPUB-08513445
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In rats given DMBA, the animals' own serum cross-reactive thymosin alpha‑1 increased within 2 hours of treatment.

    In plain wordsIn rats given a tumor-causing chemical, the body's own thymosin alpha‑1 in blood rose within 2 hours.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum CRT alpha 1 within 2 h of DMBA
    Study

    ratn: not reported in source

    Female Sprague-Dawley rats given DMBA to induce mammary tumors
    Comparator
    Matched control rats
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    An increase in CRT alpha 1 in DMBA-treated animals was observed within 2 h of DMBA treatment.
    1 context sentence
    Summary · context
    The levels of serum cross-reactive thymosin alpha 1 (CRT alpha 1) were measured at various time intervals during the course of development of mammary tumors in female Sprague-Dawley rats intubated with 7,12-dimethylbenz[a]-anthracene (DMBA; 10 mg/rat).

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In DMBA-treated rats, the animals' own serum cross-reactive thymosin alpha‑1 stayed elevated for another 3 weeks and then declined to control levels.

    In plain wordsIn rats given a tumor-causing chemical, the body's own thymosin alpha‑1 stayed high for 3 more weeks, then fell back to normal.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedSerum CRT alpha 1 over 3 weeks after DMBA
    Study

    ratn: not reported in source

    Female Sprague-Dawley rats given DMBA to induce mammary tumors
    Comparator
    Matched control rats
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Thereafter the levels of CRT alpha 1 in the serum of the DMBA-treated rats remained elevated for another 3 weeks prior to declining to control levels.
    1 context sentence
    Summary · context
    The levels of serum cross-reactive thymosin alpha 1 (CRT alpha 1) were measured at various time intervals during the course of development of mammary tumors in female Sprague-Dawley rats intubated with 7,12-dimethylbenz[a]-anthracene (DMBA; 10 mg/rat).

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Other

    In DMBA-treated rats, the animals' own serum cross-reactive thymosin alpha‑1 increased again at 9-11 weeks, when mammary tumors were palpable or observed.

    In plain wordsIn rats given a tumor-causing chemical, the body's own thymosin alpha‑1 rose again at 9-11 weeks, when tumors appeared.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum CRT alpha 1 at 9-11 weeks after DMBA
    Study

    ratn: not reported in source

    Female Sprague-Dawley rats given DMBA to induce mammary tumors
    Comparator
    Matched control rats
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Levels remained stationary until an increase in serum CRT alpha 1 was observed at 9-11 weeks post-DMBA treatment. This correlated with the time when mammary tumors were either palpable or observed.
    1 context sentence
    Summary · context
    The levels of serum cross-reactive thymosin alpha 1 (CRT alpha 1) were measured at various time intervals during the course of development of mammary tumors in female Sprague-Dawley rats intubated with 7,12-dimethylbenz[a]-anthracene (DMBA; 10 mg/rat).

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  4. 04AnimalEndogenous levelAnimal study (in vivo)Other

    In DMBA-treated rats, the animals' own serum cross-reactive thymosin alpha‑1 fell at 13 weeks but stayed slightly elevated until sacrifice at 18 weeks.

    In plain wordsIn rats given a tumor-causing chemical, the body's own thymosin alpha‑1 fell at 13 weeks but stayed slightly raised until week 18.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedSerum CRT alpha 1 at 13 to 18 weeks after DMBA
    Study

    ratn: not reported in source

    Female Sprague-Dawley rats given DMBA to induce mammary tumors
    Comparator
    Matched control rats
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Levels of CRT alpha 1 fell at 13 weeks but remained slightly elevated until sacrifice due to tumor burden at 18 weeks.
    1 context sentence
    Summary · context
    The levels of serum cross-reactive thymosin alpha 1 (CRT alpha 1) were measured at various time intervals during the course of development of mammary tumors in female Sprague-Dawley rats intubated with 7,12-dimethylbenz[a]-anthracene (DMBA; 10 mg/rat).

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.